Systemic mastocytosis (SM) is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent SM, aggressive SM, and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: SM with an associated hematological neoplasm, which is characterized by the presence of a concurrent neoplasm, more commonly, a chronic myelomonocytic leukemia. While KIT D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied. Treatment of SM might not be simple, but now more specific therapies tailored toward prognostic subgroups of patients have been developed. Here, we report a detailed description of clinical management and biological features of a systemic mastocytocis case associated with multiple hematologic non–mast cell lineage diseases.
A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases / Grifoni, F.I., Sciumè, M., Pravettoni, V., Ulivieri, F.M., Muratori, S., Fracchiolla, N.S., Tagliaferri, E., Gianelli, U., Migliorini, A.C., Cro, L., Pacilli, A., Mannelli, F., Baldini, L.. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 1099-1069. - ELETTRONICO. - 37:(2019), pp. 205-211. [10.1002/hon.2605]
A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases
Pacilli, Annalisa;Mannelli, Francesco;Baldini, Luca
2019
Abstract
Systemic mastocytosis (SM) is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent SM, aggressive SM, and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: SM with an associated hematological neoplasm, which is characterized by the presence of a concurrent neoplasm, more commonly, a chronic myelomonocytic leukemia. While KIT D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied. Treatment of SM might not be simple, but now more specific therapies tailored toward prognostic subgroups of patients have been developed. Here, we report a detailed description of clinical management and biological features of a systemic mastocytocis case associated with multiple hematologic non–mast cell lineage diseases.| File | Dimensione | Formato | |
|---|---|---|---|
|
Grifoni Hematol Oncol 2019.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Solo lettura
Dimensione
1.21 MB
Formato
Adobe PDF
|
1.21 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



